News

Cancel
  • The new Medical Device Regulation (MDR) that became effective in summer 2017 poses a challenge in particular for small and medium-sized biomedical engineering enterprises, since it requires conformity evaluation not only of future innovations, but also reassessment of existing products. Initiated by the High Performance Center Translational Biomedical Engineering, representatives from industry and academia discussed the issue of medical device safety during the meeting of the expert panel on functional interfaces of the VDE/VDI Society Microelectronics, Microsystems and Precision Engineering in Frankfurt (Germany) on January 22, 2018.

    more info
  • Fraunhofer ITEM tested a COPD drug from Novartis Pharma GmbH for its potential to improve heart function / 2018

    Innovative clinical study: a successful step in COPD research

    News / 22.2.2018

    In a clinical trial performed at the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, administration of a combination drug from Novartis (incacaterol/glycopyrronium) was shown to improve not only lung function in COPD patients, but to have a significantly positive effect on their heart function as well. The results of this study have now been published in the renowned journal “The Lancet Respiratory Medicine”.

    more info
  • CRACK IT Challenge competition 2017 / 2018

    Great success for Fraunhofer ITEM scientists

    News / 21.2.2018

    Two Fraunhofer ITEM scientists have been awarded funding for their projects in the 2017 CRACK IT Challenge competition. The CRACK IT Challenge is the NC3Rs’ response to the changing environment in the biosciences. The NC3Rs is a UK-based scientific organization dedicated to replacing, refining and reducing the use of animals in research and testing.

    more info
  • Prof. Schlüter, member of the board of trustees of the Fraunhofer ITEM, passed away / 2018

    Obituary: Professor Gerhard Schlüter

    News / 12.2.2018

    Professor Gerhard Schlüter, 78, passed away on January 30, 2018. His death means that we have lost not only a dedicated toxicologist but also a close companion.

    more info
  • Fraunhofer scientist reappointed to committee / 2017

    Dr. Oliver Licht has been reappointed to the BfR Committee

    News / 13.12.2017

    Together with experts from federal and Länder authorities, universities, and other research institutions, Fraunhofer ITEM scientists act as external, independent consultants to the German Federal Institute for Risk Assessment (BfR). In a transparent process following a public call, the experts are selected by an appointing panel based on their personal expertise and are then appointed to this honorary post by the BfR president.

    more info
  • A new technology at Fraunhofer ITEM / 2017

    Chip cytometry: chip-based cell analysis

    News / 13.12.2017

    Chip cytometry is based on the immobilization of cells on special object slides referred to as chips. On such chips, cells can be studied with respect to morphology, expression of surface markers, and intracellular function. Consecutive, iterative staining processes allow a comprehensive immunological and functional characterization of cells. This method enables investigations at the single-cell level and, depending on the cell population, the chips can be stored for up to two years.

    more info
  • Three strong partners have joined forces in a research collaboration aimed at developing novel in-vitro test systems with muscle cells from different tissue regions: Aspect Biosystems Ltd. (Vancouver, Canada), InSCREENeX GmbH (Braunschweig, Germany), and Fraunhofer ITEM (Hannover, Germany). The collaboration is supported by the Canadian National Research Council – Industrial Research Assistance Program (NRC-IRAP) and the German Federal Ministry for Economic Affairs and Energy – Central Innovation Program for SMEs (BMWi-ZIM).

    more info
  • The Working Group on “high-throughput drug and target discovery” started at Fraunhofer ITEM in Regensburg in September 2017. In collaboration with Assay.Works GmbH, the group aims to generate a panel of patient-derived cellular cancer models by systematic optimization of growth and expansion conditions, followed by their use in high-throughput compound, RNAi and CRISPR-Cas9 screens for drug and target discovery projects in oncology.

    more info
  • Formal opening of “Science Campus Braunschweig-Süd” / 2017

    Life science campus with a focus on translation

    6.10.2017

    On October 6, 2017, the “Science Campus Braunschweig-Süd” was formally opened by Lower Saxony Minister of Science and Culture Gabriele Heinen-Kljajić and Braunschweig’s Oberbürgermeister (Lord Mayor) Ulrich Markurth.

    more info